A new study from Washington University School of Medicine in St. Louis found that people who stop taking GLP-1 receptor agonists—such as semaglutide and tirzepatide—lose cardiovascular health benefits provided by the medications. The observational study followed more than 333,000 U.S. veterans with type 2 diabetes for about three years, comparing those taking GLP-1s to those taking sulfonylureas, a different class of diabetes medication.
Key Findings on Benefit Erosion
Researchers found that those who used GLP-1s continuously for three years had an 18% reduction in cardiovascular risk. However, stopping the medication rapidly eroded these benefits: stopping for six months raised the risk by 4%, one year off the medication elevated it by 14%, and two years of non-use raised the risk by 22%. The study was published in BMJ Medicine. Ziad Al-Aly, senior clinical epidemiologist at WashU Medicine, expressed surprise at the pace: “We expected some loss of benefit after stopping, but the pace was striking. Protection that takes years to accumulate can vanish in a few months of stopping.”
Metabolic Changes and Partial Recovery
GLP-1 drugs reduce not only weight but also cholesterol, blood pressure, inflammation, and insulin resistance. When people stop, these start moving in the wrong direction. When patients restarted GLP-1s after quitting, they experienced a partial but not full heart health benefit. Al-Aly emphasized: “Restarting helped, but it didn’t fully restore the protection of uninterrupted use. Discontinuation leaves a lasting scar. That tells us the damage from stopping isn’t fully reversible, and that has real implications for the millions of people cycling on and off these drugs.” Researchers characterize the reversal of metabolic benefits as “metabolic whiplash,” noting that when people stop GLP-1 drugs, there is a resurgence in inflammation, blood pressure, cholesterol, and insulin resistance. Unlike weight regain, this metabolic reversal is “silent and invisible” until it surfaces as a heart attack or stroke.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://us.headtopics.com/news/stopping-glp-1-drugs-like-ozempic-erodes-heart-health-81387208